Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Multicenter Study
. 2025 Nov;22(11):2784-2790.
doi: 10.1016/j.hrthm.2025.02.040. Epub 2025 May 6.

Anticoagulation in critically ill patients with new-onset atrial fibrillation: Insights from a retrospective cohort study

Affiliations
Multicenter Study

Anticoagulation in critically ill patients with new-onset atrial fibrillation: Insights from a retrospective cohort study

Larissa Bianchini et al. Heart Rhythm. 2025 Nov.

Abstract

Background: New-onset atrial fibrillation (NOAF) is associated with worse short-term prognosis among critically ill patients, and the benefit of anticoagulation is uncertain.

Objective: We aimed to evaluate whether anticoagulation at hospital discharge for critically ill patients presenting with NOAF is associated with improved survival.

Methods: Retrospective Cohort Study using the Medical Information Mart for Intensive Care (MIMIC)-IV database, which comprises data from patients admitted to the intensive care units (ICUs) at Beth Israel Deaconess Medical Center, Boston, Massachusetts, USA. We included patients diagnosed with NOAF during admission to ICUs between 2008 and 2019 and excluded patients with pre-existing atrial fibrillation (AF), admission related to cardiac surgery and previous anticoagulant use. We did a propensity-score matched (PSM) 1:1 to compare survival between patients discharged on anticoagulation (ACO) vs no anticoagulation and a Cox regression model to assess the primary outcome of long-term survival post-hospital discharge. We censored the patients at 3 different time points and performed another 3-sensitivity analysis to assess the robustness of the results.

Results: A total of 495 patients received ACO therapy, and 2021 patients did not. Matching demonstrated adequate covariate balance, with both groups comprising 495 patients postmatching. Out of hospital mortality rate after PSM was 30.9% vs 38.4% in the ACO and non-ACO groups, respectively. Patients in the ACO group exhibited greater long-term survival (hazard ratio [HR] 0.72, 95% CI 0.58-0.89, P = .003). The benefit was present in the PSM analysis censored at 90 days (HR 0.63, 95% CI 0.43-0.94, P = .02), 1 year (HR 0.55, 95% CI 0.41-0.793, P < .001), and 5 years (HR 0.7, 95% CI 0.56-0.88, P = .002).These findings also remained consistent across the 3 other sensitivity analyses performed.

Conclusion: Anticoagulant prescription at hospital discharge for patients with NOAF during ICU stay was associated with longer survival.

Keywords: Anticoagulation; Critically ill; Intensive care; New-onset atrial fibrillation; Warfarin.

PubMed Disclaimer

Conflict of interest statement

Disclosures Dr de Barros e Silva has received fees and research grants from Roche Diagnostics, Novartis, and Bayer. The other authors have no conflicts of interest to disclose.

Publication types

MeSH terms

LinkOut - more resources